Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control

Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...

Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary ...

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ...
Morningstar

PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary Fibrosis

Feedback from U.S. Food and Drug Administration (FDA) supports advancement into a pivotal Phase 3 trial and a 505(b)(2) regulatory pathway Phase 3 SURPASS-IPF trial remains on track to be initiated by ...
GEN

Insilico Eyes Q4 Start for Late-Stage Trials of IPF Candidate

Artificial intelligence (AI) drug developer Insilico Medicine says it is planning late-stage trials for its lead clinical candidate rentosertib following publication today of positive mid-stage safety ...
Nature

Treatments for idiopathic pulmonary fibrosis are on the horizon

Even a disease as deadly as idiopathic pulmonary fibrosis (IPF) can start out as just a cough. But as the condition progresses, a person might experience up to 500 respiratory spasms per day.